抗HGF Receptor抗体(Anti-HGF Receptor, c-Met, Human, Goat-Poly, Biotin antibody)

掲載日情報:2021/01/28 現在Webページ番号:27604

HGF Receptorに対する抗体(Anti-HGF Receptor, c-Met, Human, Goat-Poly, Biotin )です。
本製品は研究用です。研究用以外には使用できません。

価格

[在庫・価格 :2024年05月18日 00時00分現在]

※ 表示されている納期は弊社に在庫が無く、取り寄せた場合の納期目安となります。
詳細 商品名
  • 商品コード
  • メーカー
  • 包装
  • 価格
  • 在庫
  • 法規制等
納期 文献数
Anti-HGF Receptor, c-Met, Human, Goat-Poly, Biotin
10日程度 ※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。 9
説明文
マッチドペア:Human HGF R/c-MET サンドイッチELISAの検出用抗体として利用可能,補足用抗体として#MAB3581-500,スタンダードとして#358-MT-100を用いる。
別名:AUTS9
Genbank No: 4233
Protein Accession No: P08581
法規制等
保存条件 -20℃ 法規備考
抗原種 Human 免疫動物 Goat クラス IgG 標識 Biotin
交差性 Human 適用 ELISA,FCM,Western Blot
クロナリティ Polyclonal フォーマット 性状 Antigen Affinity Purified 吸収処理
掲載カタログ

製品記事
関連記事 R&D Systems(R&Dシステムズ)社 ELISA用ペア抗体を使用したELISA 構築ガイド

[在庫・価格 :2024年05月18日 00時00分現在]

※ 表示されている納期は弊社に在庫が無く、取り寄せた場合の納期目安となります。

Anti-HGF Receptor, c-Met, Human, Goat-Poly, Biotin

文献数: 9

説明文 マッチドペア:Human HGF R/c-MET サンドイッチELISAの検出用抗体として利用可能,補足用抗体として#MAB3581-500,スタンダードとして#358-MT-100を用いる。
別名:AUTS9
Genbank No: 4233
Protein Accession No: P08581
法規制等
保存条件 -20℃ 法規備考
抗原種 Human 免疫動物 Goat
交差性 Human 適用 ELISA,FCM,Western Blot
標識 Biotin 性状 Antigen Affinity Purified
吸収処理 クラス IgG
クロナリティ Polyclonal フォーマット
掲載カタログ

製品記事
関連記事 R&D Systems(R&Dシステムズ)社 ELISA用ペア抗体を使用したELISA 構築ガイド



目次に戻る

Product Details

Species ReactivityHuman
LabelBiotin
ImmunogenMouse myeloma cell line NS0-derived recombinant human HGF R/c-METGlu25-Thr932Accession # P08581
SourcePolyclonal Goat IgG
PurificationAntigen Affinity-purified
SpecificityDetects human HGF R/c-MET in ELISAs and Western blots. In Western blot, this antibody shows approximately 50% cross-reactivity with recombinant mouse HGF R.


目次に戻る

Applications and Data

 Recommended
Concentration
Sample
Western Blot0.1 µg/mLRecombinant Human HGF R/c-MET Fc Chimera (Catalog # 358-MT)
Flow Cytometry2.5 µg/106 cellsSee below
Human HGF R/c-MET Sandwich ImmunoassayReagent
ELISA Capture (Matched Antibody Pair)2-8 µg/mL Human HGF R/c‑MET Antibody (Catalog #MAB3581 )
ELISA Detection (Matched Antibody Pair)0.1-0.4 µg/mL Human HGF R/c‑MET Biotinylated Antibody (Catalog #BAF358 )
ELISA Standard  Recombinant Human HGF R/c-MET Fc Chimera His-tag Protein (Catalog #358-MT )
Please Note: Optimal dilutions should be determined by each laboratory for each application.General Protocolsare available in the Technical Information section on our website.

目次に戻る

Data Examples

Flow Cytometry Flow Cytometry HGF R/c-MET Antibody [Biotin]
click image to view larger
Detection of HGF R/c‑MET in MDA‑MB‑231 Human Cell Line by Flow Cytometry.MDA‑MB‑231 human breast cancer cell line was stained with Human HGF R/c‑MET Biotinylated Antigen Affinity‑purified Polyclonal Antibody (Catalog # BAF358, filled histogram) or control antibody (Catalog # BAF108, open histogram), followed by Streptavidin-Allophycocyanin (Catalog # F0050).
ReconstitutionReconstitute at 0.2 mg/mL in sterile PBS.Reconstitution Buffer Available
ShippingThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: HGF R/c-MET

HGF R, also known as Met (from N-methyl-N’-nitro-N-nitrosoguanidine induced), is a glycosylated receptor tyrosine kinase that plays a central role in epithelial morphogenesis and cancer development. HGF R is synthesized as a single chain precursor which undergoes cotranslational proteolytic cleavage. This generates a mature HGF R that is a disulfide-linked dimer composed of a 50 kDa extracellular alpha chain and a 145 kDa transmembrane beta chain (1, 2). The extracellular domain (ECD) contains a seven bladed beta -propeller sema domain, a cysteine-rich PSI/MRS, and four Ig-like E-set domains, while the cytoplasmic region includes the tyrosine kinase domain (3, 4). Proteolysis and alternate splicing generate additional forms of human HGF R which either lack the kinase domain, consist of secreted extracellular domains, or are deficient in proteolytic separation of the alpha and beta chains (5-7). The sema domain, which is formed by both the alpha and beta chains of HGF R, mediates both ligand binding and receptor dimerization (3, 8). Ligand-induced tyrosine phosphorylation in the cytoplasmic region activates the kinase domain and provides docking sites for multiple SH2-containing molecules (9, 10). HGF stimulation induces HGF R downregulation via internalization and proteasome-dependent degradation (11). In the absence of ligand, HGF R forms noncovalent complexes with a variety of membrane proteins including CD44v6, CD151, EGF R, Fas, Integrin alpha 6/ beta 4, Plexins B1, 2, 3, and MSP R/Ron (12-19). Ligation of one complex component triggers activation of the other, followed by cooperative signaling effects (12-19). Formation of some of these heteromeric complexes is a requirement for epithelial cell morphogenesis and tumor cell invasion (12, 16, 17). Paracrine induction of epithelial cell scattering and branching tubulogenesis results from the stimulation of HGF R on undifferentiated epithelium by HGF released from neighboring mesenchymal cells (20). Genetic polymorphisms, chromosomal translocation, overexpression, and additional splicing and proteolytic cleavage of HGF R have been described in a wide range of cancers (1). Within the ECD, human HGF R shares 86-88% aa sequence identity with canine, mouse, and rat HGF R.

目次に戻る

References

Birchmeier, C. et al. (2003) Nat. Rev. Mol. Cell Biol. 4:915.
Corso, S. et al. (2005) Trends Mol. Med. 11:284.
Gherardi, E. et al. (2003) Proc. Natl. Acad. Sci. USA 100:12039.
Park, M. et al. (1987) Proc. Natl. Acad. Sci. USA 84:6379.
Crepaldi, T. et al. (1994) J. Biol. Chem. 269:1750.
Prat, M. et al. (1991) Mol. Cell. Biol. 12:5954.
Rodrigues, G.A. et al. (1991) Mol. Cell. Biol. 11:2962.
Kong-Beltran, M. et al. (2004) Cancer Cell 6:75.
Naldini, L. et al. (1991) Mol. Cell. Biol. 11:1793.
Ponzetto, C. et al. (1994) Cell 77:261.
Jeffers, M. et al. (1997) Mol. Cell. Biol. 17:799.
Orian-Rousseau, V. et al. (2002) Genes Dev. 16:3074.
Klosek, S.K. et al. (2005) Biochem. Biophys. Res. Commun. 336:408.
Jo, M. et al. (2000) J. Biol. Chem. 275:8806.
Wang, X. et al. (2002) Mol. Cell 9:411.
Trusolino, L. et al. (2001) Cell 107:643.
Giordano, S. et al. (2002) Nat. Cell Biol. 4:720.
Conrotto, P. et al. (2004) Oncogene 23:5131.
Follenzi, A. et al. (2000) Oncogene 19:3041.
Sonnenberg, E. et al. (1993) J. Cell Biol. 123:223.
Long Name:Hepatocyte Growth Factor Receptor
Entrez Gene IDs:4233 (Human); 17295 (Mouse)
Alternate Names:AUTS9; cMET; c-MET; EC 2.7.10; EC 2.7.10.1; hepatocyte growth factor receptor; HGF R; HGF receptor; HGF/SF receptor; HGFR; Met (c-Met); met proto-oncogene (hepatocyte growth factor receptor); met proto-oncogene tyrosine kinase; MET; oncogene MET; Proto-oncogene c-Met; RCCP2; Scatter factor receptor; SF receptor; Tyrosine-protein kinase Met

目次に戻る

Related Research Areas

Cancer Biomarkers
Cancer Stem Cell Markers
Cytokine and Growth Factor Receptors on VSMC
Cytokines and Receptors in Angiogenesis
Hepatic Endoderm
Hepatic Endoderm Cell Markers
HIF Transcription Factors
Receptor Tyrosine Kinases (RTKs)
Receptor Tyrosine Kinases (RTKs) in the Akt Pathway
Receptors in the Jak/STAT Pathway
  1. Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer
    Authors: Deborah R Kaye
    PLoS ONE, 2016;11(6):e0157130.
    Species: Human
    Sample Type: Whole Tissue
    Application: ELISA Capture


Flow Cytometry
Detection of HGF R/c‑MET in MDA‑MB‑231 Human Cell Line by Flow Cytometry.
MDA‑MB‑231 human breast cancer cell line was stained with Human HGF R/c‑MET Biotinylated Antigen Affinity‑purified Polyclonal Antibody (Catalog # BAF358, filled histogram) or control antibody (Catalog # BAF108, open histogram), followed by Streptavidin-Allophycocyanin (Catalog # F0050).


目次に戻る

Related Product & Information

BackgroundHGF R/c-MET
background_contentBackground:
HGF R/c-MET
HGF R, also known as Met (from N-methyl-N’-nitro-N-nitrosoguanidine induced), is a glycosylated receptor tyrosine kinase that plays a central role in epithelial morphogenesis and cancer development. HGF R is synthesized as a single chain precursor which undergoes cotranslational proteolytic cleavage. This generates a mature HGF R that is a disulfide-linked dimer composed of a 50 kDa extracellular alpha chain and a 145 kDa transmembrane beta chain (1, 2). The extracellular domain (ECD) contains a seven bladed beta -propeller sema domain, a cysteine-rich PSI/MRS, and four Ig-like E-set domains, while the cytoplasmic region includes the tyrosine kinase domain (3, 4). Proteolysis and alternate splicing generate additional forms of human HGF R which either lack the kinase domain, consist of secreted extracellular domains, or are deficient in proteolytic separation of the alpha and beta chains (5-7). The sema domain, which is formed by both the alpha and beta chains of HGF R, mediates both ligand binding and receptor dimerization (3, 8). Ligand-induced tyrosine phosphorylation in the cytoplasmic region activates the kinase domain and provides docking sites for multiple SH2-containing molecules (9, 10). HGF stimulation induces HGF R downregulation via internalization and proteasome-dependent degradation (11). In the absence of ligand, HGF R forms noncovalent complexes with a variety of membrane proteins including CD44v6, CD151, EGF R, Fas, Integrin alpha 6/ beta 4, Plexins B1, 2, 3, and MSP R/Ron (12-19). Ligation of one complex component triggers activation of the other, followed by cooperative signaling effects (12-19). Formation of some of these heteromeric complexes is a requirement for epithelial cell morphogenesis and tumor cell invasion (12, 16, 17). Paracrine induction of epithelial cell scattering and branching tubulogenesis results from the stimulation of HGF R on undifferentiated epithelium by HGF released from neighboring mesenchymal cells (20). Genetic polymorphisms, chromosomal translocation, overexpression, and additional splicing and proteolytic cleavage of HGF R have been described in a wide range of cancers (1). Within the ECD, human HGF R shares 86-88% aa sequence identity with canine, mouse, and rat HGF R.


目次に戻る

Citations

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
  1. Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer
    Authors: Deborah R Kaye
    PLoS ONE, 2016;11(6):e0157130.
    Species: Human
    Sample Type: Whole Tissue
    Application: ELISA Capture

  2. A pharmacodynamic/pharmacokinetic study of ficlatuzumab in patients with advanced solid tumors and liver metastases.
    Authors: Tabernero J, Elez M, Herranz M, Rico I, Prudkin L, Andreu J, Mateos J, Carreras M, Han M, Gifford J, Credi M, Yin W, Agarwal S, Komarnitsky P, Baselga J
    Clin Cancer Res, 2014;20(10):2793-804.
    Species: Human
    Sample Type: Serum
    Application: ELISA Capture

  3. The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling.
    Authors: Cen B, Xiong Y, Song J, Mahajan S, DuPont R, McEachern K, DeAngelo D, Cortes J, Minden M, Ebens A, Mims A, LaRue A, Kraft A
    Mol Cell Biol, 2014;34(13):2517-32.
    Species: Human
    Sample Type: Cell Lysates
    Application: WB

  4. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.
    Authors: Gordon MS, Sweeney CS, Mendelson DS
    Clin. Cancer Res., 2010;16(2):699-710.
    Species: Human
    Sample Type: Plasma
    Application: Electrochemiluminescent Assay

  5. Soluble c-Met receptors inhibit phosphorylation of c-Met and growth of hepatocyte growth factor: c-Met-dependent tumors in animal models.
    Authors: Coxon A, Rex K, Meyer S, Sun J, Sun J, Chen Q, Radinsky R, Kendall R, Burgess TL
    Mol. Cancer Ther., 2009;0(0):.
    Species: Human
    Sample Type: Cell Lysates
    Application: Electrochemiluminescence



目次に戻る

お問い合わせ先

(テクニカルサポート 試薬担当)

reagent@funakoshi.co.jp

製品情報は掲載時点のものですが、価格表内の価格については随時最新のものに更新されます。お問い合わせいただくタイミングにより製品情報・価格などは変更されている場合があります。
表示価格に、消費税等は含まれていません。一部価格が予告なく変更される場合がありますので、あらかじめご了承下さい。